NZX-listed Fisher & Paykel Healthcare has lifted guidance for the 2020 financial year on the back of increased demand in China as a result of the Covid-19 coronavirus epidemic.
The Auckland-based healthcare product manufacturer has lifted its guidance for operating revenue to $1.2 billion and
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
